Thinly traded nano cap SCYNEXIS (SCYX +11%) is up on more than a 4x surge in volume in reaction to the completion of the last visit for the last patient in its Phase 3 clinical trial, VANISH 303, evaluating ibrexafungerp (formerly SCY-078) for the treatment of fungal infections, in both outpatient and inpatient settings. Topline data should be available in Q2 2020.
A data readout from a second Phase 3, VANISH 306, should also be available in Q2 2020.
If all goes well, the company expects to file a U.S. marketing application in H2 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.